Selected Publications
1. Jalian HR, Liu PT, Kanchanapoomi M, Legaspi A, Modlin RL, Kim J. All-trans retinoic acid downregulates Propionibacterium acnes induced matrix metalloproteinase-1,9 and upregulates tissue inhibitors of metalloproteinase-1 in human monocytes. Journal of Investigative Dermatology 19 June 2008; doi:10.1038/jid.2008.
2. Liu PT, Phan J, Tang D, Kanchanapoomi M, Hall B, Krutzik SR, Kim J. CD209+ macrophages mediate host defense against Propionibacterium acnes. Journal of Immunology 180:4919-23, 2008.
3. McInturff J, Kim J. The Role of Toll: How therapies targeting Toll-like Receptors treat skin diseases. Drug Discovery Today:Therapeutic Strategies 3:75-80, 2006.
4. Liu P, Krutzik S, Kim J, Modlin R. Cutting edge: All-trans retinoic acid downregulates Toll-like receptor-2 expression and function. Journal of Immunology, 174:2467-2470, 2005.
5. McInturff J, Wang S-J, Machleidt T, Lin R, Oren A, Hertz C, Krutzik S, Hart S, Zeh K, Anderson D, Gallo R, Modlin RL, Kim J. Granulysin-derived Peptides Demonstrate Antimicrobial and Antiinflammatory Activity against Propionibacterium acnes. J Invest Dermatol 125:256-263, 2005.
6. Lee DJ, Van Dyke GS, Kim J. Update on pathogenesis of acne. Curr Opin Pediatr, 15:405-410, 2003.
7. Arora T, Liu B, He H, Kim J, Murphy TL, Murphy KM, Modlin RL, Shuai K. Inhibition of Stat-4-mediated gene activation by PIASx. J Biol Chem 278:21327-21330, 2003.
8. Kim J, Ochoa MT, Krutzik S, Takeuchi O, Uematsu S, Legaspi A, Brightbill H, Holland D, Cunliffe WJ, Akira S, Sieling PA, Godowski PJ, Modlin RL. Activation of Inflammatory Cytokine Responses in Acne Occurs through Toll-like Receptor 2. Journal of Immunology, 169:1535-1541, 2002.
9. Grimes PE, Bhawan J, Kim J, Chiu M, Lask G. Laser resurfacing-induced hypopigmentation: histologic alterations and repigmentation with topical photochemotherapy. Dermatol Surg 27:515-520, 2001.
10. Kim J, Uyemura K, Van Dyke MK, Legaspi A, Presky DH, Rea TH, Shuai K, Modlin RL. A role for IL-12 receptor expression and signal transduction in host defense in leprosy. J Immunol 167:779-786, 2001.
11. Yamauchi PS, Bleharski JR, Uyemura K, Kim J, Sieling PA, Miller A, Brightbill H, Schlienger K, Rea TH, Modlin RL. A role for CD40-CD40 ligand interactions in the generation of type 1 cytokine responses in human leprosy. J Immunol 165:1506-1512, 2000.
12. Kim J, Beddingfield FC, Lask GP. Non-ablative facial resurfacing. Operative Techniques in Oculoplastic, Orbital, and Reconstructive Surgery 3:55-57, 2000.
13. Kim J, Sette A, Rodda S, Southwood S, Mehra V, Oliveros J, Sieling PA, Rea TH, Bloom BR, Modlin RL. Determinants of T-cell reactivity to the Mycobacterium leprae GroES homolog. J Immunol 159:335-343, 1997.
14. Kim J, Modlin RL, Moy RL, Dubinett S, McHugh T, Nickoloff BJ, Uyemura K. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T Cell immune response. J Immunol 155: 2240-2247, 1995.
15. Ohmen JD, Hanifin JM, Nickoloff BJ, Rea TH, Wyzykowski R, Kim J, Jullien D, McHugh T, Nassif AS, Chan SC, Modlin RL. Overexpression of IL-10 in atopic dermatitis. J Immunol 154:1956-1963, 1995.
Research Interests:
Dr. Kim conducts both basic and clinical research in dermatologic science. In particular, her
interest is in translational medicine, bringing scientific results from the bench to the bedside.
Dr. Kim's laboratory currently focuses on three specific areas:
- Studying innate immunity in skin diseases.
- Investigating the mechanisms of inflammation, aging, and cancer.
- Developing novel therapy for skin infection, aging and cancer.
Dr. Kim is involved with clinical trials that focus on anti-aging, aesthetic dermatology and new dermatology therapies that are immune-based. Current active clinical trial include the following:
- Treatment of melomental fold rhytides with Nonanimal Sourced Hyaluronic Acid (NASHA) combined with Botulism toxin A (Botox) compared with NASHA alone.
|
